AFCAPS/TexCAPS

Air Force Coronary/Texas Atherosclerosis Prevention Study. A clinical trial used to assess primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.
Conclusion Lovastatin reduces LDL-C by 25%, raises HDL-C by 6%, and decreases major acute coronary events, unstable angina, coronary revascularization, coronary events, and other vascular events.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.